Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Kidney cancer in 2016

RCC — advances in targeted therapeutics and genomics

Nature Reviews Urology volume 14, pages 76–78 (2017)Cite this article

Subjects

Recent advances have been exciting in the genomics of and targeted therapeutics for renal cell carcinoma (RCC). New agents have been approved for advanced RCC, a novel agent targeting hypoxia-inducible factor 2α has shown considerable promise and molecular characterization of papillary RCC provides the foundation for development of targeted therapeutic approaches for this disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Recent advances in treatment and characterization of renal cell carcinoma.

References

  1. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010).

    Article  CAS  Google Scholar 

  2. Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917–927 (2016).

    Article  CAS  Google Scholar 

  3. Motzer, R. J., Hutson, T. E., Ren, M., Dutcus, C. & Larkin, J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 17, e4–e5 (2016).

    Article  Google Scholar 

  4. Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1611406 (2016).

  5. Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117 (2016).

    Article  CAS  Google Scholar 

  6. Cho, H. et al. On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models. Nature 539, 107–111 (2016).

    Article  CAS  Google Scholar 

  7. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

  8. Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330 (2014).

    Article  CAS  Google Scholar 

  9. The Cancer Genome Atlas Research Network et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135–145 (2016).

  10. Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat. Rev. Urol. 11, 465–475 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. W. Marston Linehan and Christopher J. Ricketts are at Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892–1107, USA.,

    W. Marston Linehan & Christopher J. Ricketts

Authors
  1. W. Marston Linehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Ricketts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Marston Linehan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Linehan, W., Ricketts, C. RCC — advances in targeted therapeutics and genomics. Nat Rev Urol 14, 76–78 (2017). https://doi.org/10.1038/nrurol.2016.260

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.260

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer